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Recent meta-analysis of randomized trials comparing cisplatin
(CDDP)-based chemotherapy with best supportive care in patients
with advanced non-small cell lung cancer (NSCLC) demonstrated
some degree of survival benefit for CDDP-based chemotherapy
(Grilli et al, 1993; Souquet et al, 1993; Non-small Cell Lung
Cancer Collaborative Group, 1995). However, this benefit of
improved survival was extremely limited. In one previous report,
an objective response rate, a median survival time (MST), and a 
1-year survival rate of advanced NSCLC patients receiving
CDDP-based chemotherapy averaged approximately 25%, 6
months, and less than 20%, respectively (Johnson, 2000). In an
attempt to improve these disappointing treatment outcomes of
advanced NSCLC, several newly developed agents such as
vinorelbine, taxans, gemcitabine and topoisomerase I inhibitors
have been introduced in the 1990s (Bunn and Kelly, 1998). 
Irinotecan (CPT-11) is a semisynthetic derivative of camp-
tothecin that is metabolized in vivo to an active metabolite, SN-38,
and exerts its cytotoxic activity by inhibiting a nuclear enzyme to-
poisomearase I (Kunimoto et al, 1987; Hsiang and Liu, 1988).
CPT-11 has been shown to have a remarkable activity as a single
agent for NSCLC (Negoro et al, 1991; Fukuoka et al, 1992). Since
CDDP, a recent key drug in the treatment of NSCLC, has a
different mechanism of action and a toxicity profile from CPT-11,
and furthermore synergism between these 2 drugs was demon-
strated in vitro (Kudoh et al, 1993), combination of CDDP and
CPT-11 has been studied (Masuda et al, 1992, 1994, 1998; DeVore
et al, 1999). In a Japanese multi-institutional study, CDDP was
given on day 1 and CPT-11 on days 1, 8 and 15. An objective
response rate in the study remained to be about 50%, because
dose-escalation was prevented by diarrhoea and leukopenia which
were mainly caused by CPT-11 (Masuda et al, 1992, 1994, 1998).
In order to take maximum advantage of the synergistic effects
between CDDP and CPT-11 and to reduce the dose of CPT-11,
Okayama Lung Cancer Study Group planned the fractionated
administration in which both CDDP and CPT-11 were given on
days 1 and 8, and has already performed a phase I study (Ueoka 
et al, 1999). The present phase II study was planned to investigate
the effectiveness of this fractionated administration of CDDP and
CPT-11. The primary objective of this study was to determine the
response rate, and secondary objectives were to evaluate survival
and safety of this combination. 
MATERIALS AND METHODS 
Patient selection 
Eligibility requirements for entry into this study were as follows:
(1) histologically or cytologically proven NSCLC; (2) stage IIIB
or IV; (3) no prior chemotherapy, radiotherapy or surgery; (4)
performance status (PS) of 0–2 on the Eastern Cooperative
Oncology Group (ECOG) scale (Oken et al, 1982); (5) age 75
years or less; (6) presence of bidimensionally measurable disease;
Fractionated administration of irinotecan and cisplatin
for treatment of non-small-cell lung cancer: a phase II
study of Okayama Lung Cancer Study Group 
H Ueoka1, M Tanimoto1, K Kiura1, M Tabata1, N Takigawa1, Y Segawa2, I Takata2, K Eguchi2, N Okimoto3, S Harita4, 
H Kamei5, T Shibayama6, Y Watanabe7, S Hiraki7 and M Harada1
1Department of Internal Medicine II, Okayama University Medical School, 2-5-1 Shikatacho, Okayama 700-8558, Japan; 2Department of Respiratory Medicine,
National Shikoku Cancer Center; 3Department of Internal Medicine, Kawasaki Medical School, Kawasaki Hospital; 4Department of Internal Medicine, Chugoku
Central Hospital; 5Department of Internal Medicine, Sumitomobesshi Hospital; 6Department of Internal Medicine, Okayama Health Foundation Hospital;
7Department of Internal Medicine, Okayama Red Cross General Hospital 
Summary A phase II study of fractionated administration of irinotecan (CPT-11) and cisplatin (CDDP) in patients with non-small-cell lung
cancer (NSCLC) was conducted. Between January 1996 and January 1998, 44 previously untreated patients with stage IIIB or IV NSCLC
were enrolled. CDDP at a dose of 60 mg m–2 was given first and followed by CPT-11 at a dose of 50 mg m–2. Both drugs were given by 1-hour
infusion on days 1 and 8, and repeated every 4 weeks up to 4 cycles. 42 patients were evaluated for response and 44 for survival and toxicity.
20 patients (48%: 95% confidence interval 32–63%) achieved an objective response. The median duration of responses was 8 months, and
the median survival time and the 1-year survival rate were 12.5 months and 56.8%, respectively. Major toxicities were neutropenia and
diarrhoea. Grade 3 or 4 neutropenia occurred in 70.5% of the patients and one patient died of sepsis. Grade 3 or 4 diarrhoea was experienced
in 25.0%, but manageable by conventional therapy. In conclusion, fractionated administration of CPT-11 and CDDP was highly effective for
advanced NSCLC with manageable toxicities. © 2001 Cancer Research Campaign http://www.bjcancer.com
Keywords: phase II study; irinotecan; cisplatin; fractionated administration; non-small-cell lung cancer 
9
Received 16 October 2000 
Revised 19 March 2001 
Accepted 27 March 2001 
Correspondence to: H Ueoka 
British Journal of Cancer (2001) 85(1), 9–13
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2001.1861, available online at http://www.idealibrary.com on  http://www.bjcancer.com(7) adequate functional reserves of the kidney (creatinine clear-
ance > 60 ml min–1), liver (ALT, AST < twice the upper limit of
normal), and bone marrow (a leukocyte count > 4000 ml–1 and
platelet count > 100 000 ml–1); (8) no concomitant malignancies;
and (9) a written form of informed consent. 
Stage IIIB patients whose tumours were encompassible in a
radical radiotherapy volume were excluded. Patients with sympto-
matic superior vena caval obstruction, cerebral metastases, or
previous malignancy were also ineligible. The present study was
approved by the ethical committee of the Okayama Lung Cancer
Study Group. 
Evaluation 
Staging procedures included complete medical history and phys-
ical examination, urinalysis, a complete blood cell count (CBC),
standard blood chemistry profile, 24-hour creatinine clearance
(Ccr), electrocardiogram, a chest radiograph, fiberoptic broncho-
scopy, computerized tomographic (CT) scans of the chest and
abdomen, magnetic resonance imaging of the brain, and radio-
nuclide bone scan. CBC was repeated 2 or 3 times a week, and
urinalysis, blood chemistry, 24-hour Ccr, and chest radiograph
were assessed at least once a week after initial evaluation. CT
scans of the chest were repeated once a treatment cycle. After the
completion of chemotherapy, each patient was restaged with all
the tests used during the initial work-up. Eligibility and response
of the enrolled patients were assessed by extramural reviewers.
Responses and toxicities were evaluated according to the criteria
of ECOG (Oken et al, 1982). 
Treatment plan 
Both CDDP and CPT-11 were given by 1-hour intravenous infu-
sion with an infusion pump on days 1 and 8. CDDP at a dose of
60 mg m–2 with 100 ml physiological saline was given first and
CPT-11 at a dose of 50 mg m–2 dissolved in 300 ml of physio-
logical saline was then administered. Granisetron (3 mg) or
ondansetron (4 mg) was administered intravenously just before
CDDP administration and hydration consisting of 3000 ml of
physiological saline was given after administration of CDDP and
CPT-11. When grade 3 or higher leukopenia or neutropenia
occurred, administration of recombinant human granulocyte
colony stimulating factor (rhG-CSF) was permitted under the
guidelines of the Japanese Ministry of Health and Welfare.
Loperamide was used for treatment of diarrhoea. Patients were
instructed to have loperamide at the first onset of diarrhoea.
Usually, loperamide at a dose of 1 mg was given twice a day, and
increased up to 4 mg day–1 according to the severity of diarrhoea. 
The treatment was repeated every 4 weeks up to 4 cycles unless
disease progression occurred. If grade 4 haematological toxicity or
grade 3 diarrhoea was observed in the previous cycle, the dose of
CPT-11 was reduced by 10 mg m–2 in the next cycle. The dose of
CDDP was reduced by 10 mg m–2 for development of grade 4
haematological toxicity or by 30 mg m–2 for development of grade
3 renal toxicity. If leukocyte counts were less than 2000 ml–1 or
platelet counts less than 100 000 ml–1 on day 8, both CDDP and
CPT-11 were not administered. Before the next course was started,
leukocyte and platelet counts had to be at least 3500 ml–1 or more
and 100 000 ml–1 or more, respectively. 
Statistical methods 
The primary endpoint of this study was to estimate the objective
response rate. Sample size of this study was determined on the
assumption that the expected response rate would be 70%, with 
a 95% confidence interval of ± 15%. Time to progression 
and overall survival were calculated from the date of initiation 
of therapy using the Kaplan–Meier method. Difference in survival
between 2 groups was assessed using a log-rank test. Dose-
intensity (DI) was calculated as follows; DI = actually adminis-
tered dose (mg m–2 4-week–1)/projected dose (cisplatin 120 mg m–2
4-week–1, irinotecan 100 mg m–2 4-week–1) ´ 100. Statistical
analyses were performed using SPSS Base System™ and
Advanced Statistics™ Programs (SPSS Inc, Chicago, IL, USA). 
RESULTS 
Patient characteristics 
Between January 1996 and January 1998, 44 patients were
enrolled. The median age was 61 years (range 41–75 years). 31
patients were men and 13 women. PS was 0 in 20 patients, 1 in 19
and 2 in 5. 24 patients had adenocarcinoma, 15 squamous cell
carcinoma, 4 large cell carcinoma, and 1 adenosquamous cell
carcinoma. Clinical stage was IIIB in 14 patients and IV in 30. 
Response and survival 
Responses to chemotherapy according to clinical stage and
histology are summarized in Table 1. According to intent-to-treat
analysis, 20 of the 44 patients enrolled in the study achieved a
partial response and objective response rate was 45% (95% confi-
dence interval: CI 30.5–60.5%). Since response was not evaluated
in 2 patients because of early death by sepsis on day 22 and cere-
bral infarction on day 7, response rate among 42 assessable
patients was 48% (95% CI 32–63%). The median time required to
achieve objective response was 7 weeks (range 2–13 weeks).
There were no significant differences in response rates according
to clinical stage (50% for stage IIIB patients and 43% for stage IV)
or histology (46% for adenocarcinoma, 53% for squamous cell
carcinoma, and 25% for large cell carcinoma). The median time
to progression for all patients was 8 months (range 1–49 months). 
By a median follow-up time of 24 months (range 1–51 months),
38 (86%) patients have died and only 6 (14%) were still alive. The
survival curve for 44 patients according to clinical stage is shown
in Figure 1. The MST for all patients was 12.5 months and 1-,
2- and 3-year survival rates were 56.8%, 27.2%, and 17.1%, 
respectively. According to clinical stage, survival of patients in
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Table 1 Response 
No. of PR 95% confidence 
patients (%) interval 
Total 44 20 (45) 31–61 
Stage IIIB 14 7 (50) 23–76 
IV 30 13 (43) 25–61 
Histology 
Adenocarcinoma 24 11 (46) 26–66 
Squamous cell carcinoma 15 8 (53) 29–77 
Large cell carcinoma 4 1 (25) 3–47 
Adenosquamous 1 0 stage IIIB seemed to be superior to that in stage IV, but the differ-
ence was not significant (MST: 24.5 months vs 11.0 months, 1-, 2-
and 3-year survival rates: 71.4% vs 50.0%, 34.3% vs 16.7%,
34.3% vs 10.0%, P = 0.0672). 
Toxicity 
There was one treatment-related death. This patient died of sepsis
due to severe neutropenia on day 22. Principal toxicities are listed
in Table 2. The major haematological toxicity was neutropenia and
grade 3 or 4 neutropenia was experienced in 70.5%, which was
more frequent than expected from the results of a phase I study.
However, no severe infectious complication except a fatal sepsis in
one patient occurred. RhG-CSF was given following 39 (36%) of
the 109 assessable courses. According to the number of the cycle,
rhG-CSF was used in 18 of the 43 assessable courses at first cycle
(42%, median duration of 9 days: range 3–18 days), 10 of the 33 at
the second (30%, median duration of 5.5 days: range 3–21 days), 7
of the 21 at the third (33%, median duration of 9 days: range 5–24
days), and 4 of the 12 at the fourth (33%, median duration of 6.5
days: range 4–10 days). Though grade 3 or 4 thrombocytopenia
was observed in 40.9%, no severe haemorrhagic complication was
experienced. The major non-haematological toxicity was diar-
rhoea and grade 3 or 4 diarrhoea was encountered in 25.0%. Upper
gastrointestinal toxicities were also frequent. But these toxicities
were manageable and reversible by conventional therapy. 
Dose-intensity 
12 patients (27%) completed the projected 4 cycles of chemotherapy.
The second, third and fourth cycles of chemotherapy were not
administered to 11 (25%), 23 (52%), and 32 (73%) patients,
respectively. Reasons for not completing chemotherapy included
no response (n = 22), patient’s refusal (n = 3), toxicity or death
(n = 3), disease recurrence (n = 2), and physician’s discretion 
(n = 2). DI of each agent was shown in Table 3. DI was gradually
decreased as cycles were repeated. However, in the fourth cycle,
about 80% of the projected dose could be administered. 
DISCUSSION 
We planned the present study to maximize the synergistic effect
between CDDP and CPT-11. Therefore the schedule and sequence
of administration of these 2 agents in the present study were
different from those in the previous reports. Firstly, we conducted
simultaneous administration of both drugs twice a cycle, while
they were simultaneously given once a cycle in the previous
reports. Secondly, though CPT-11 was given before CDDP admin-
istration in the Japanese multi-institutional study, we gave CDDP
before CPT-11 administration, because this sequence was better
than the inverted sequence in our in vitro study (Aoe et al, 1997). 
In a phase I study, we determined the recommended dose of
CPT-11 as 50 mg m–2 when combined with CDDP at a dose of
60 mg m–2 for the subsequent phase II study. At this dose level,
only 2 of 7 patients (29%) developed grade 3 leukopenia and no
patients developed severe non-haematological toxicities.
Chemotherapy was repeated every 4 weeks, because it took 24
days (median days from initiation of chemotherapy) until recovery
of neutrophil. The objective response rate, 76% for advanced
NSCLC, was highly hopeful (Ueoka et al, 1999). Based on these
results, we initiated the present phase II study, assuming the
expected response rate to be 70%. The previously reported results
of a combination of CDDP and CPT-11 for advanced NSCLC are
summarized in Table4 (Masuda et al, 1998, 1999; DeVore et al,
1999; Niho et al, 1999). Though the response rate obtained in this
phase II study was 45%, which was considerably lower than the
expected response rate, it was comparable to the previously
reported results. On the other hand, survival was fairly good. The
MST (54 weeks) and 1-year survival rate (57%) were better than
those reported previously with a combination of CPT-11 and
CDDP (Masuda et al, 1998, 1999; DeVore et al, 1999; Niho et al,
1999). 
The major haematological toxicity in the present study was
neutropenia. Grade 3 and 4 neutropenia occurred in 71%, which
was nearly comparable with those in the other reports, though
severe infectious complications were rare. On the other hand,
Phase II study of cisplatin and irinotecan for NSCLC 11
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Figure 1 Survival curves according to clinical stage 
Table 2 Toxicity 
Grade Grade 3/4 (%) 
01 2 3 4  
Anaemia 2 7 16 12 7 43.2 
Leukopenia 2 9 13 15 5 45.5 
Neutropenia 2 1 10 9 22 70.5 
Thrombopenia 6 15 5 12 6 40.9 
Nausea/vomiting 2 10 21 10 1 25.0 
Appetite loss 5 5 20 13 1  31.8 
Oral mucositis 40 2 1 0 1  2.3 
Diarrhoea 10 15 8 5 6 25.0 
Hair loss 9 18 17 
Neutropenic fever 29 7 7  1  2.3 
Renal damage 33 6 4 1  2.3 
Liver damage 31 8 3 1 1 4.5
Table 3 Dose intensity 
No. of Delivered dose/projected dose (%) 
Course patients Cisplatin Irinotecan 
#1 44 97.2 95.3 
#2 33 83.3 85.0 
#3 21 80.8 81.1 
#4 12 78.9 80.5 severe diarrhoea occurred in 25%, which was slightly higher than
that in the previous reports (Masuda et al, 1998, 1999; DeVore et
al, 1999; Niho et al, 1999). In the weekly administration of both
CPT-11 and CDDP conducted by Kobayashi et al under similar
consideration (Kobayashi et al, 1998), the most prominent toxicity
was leukopenia, and diarrhoea was not a dose-limiting toxicity.
CPT-11 has been considered as the major cause of diarrhoea in this
combination. However, the incidence of severe diarrhoea was the
most frequent in the present study, though DI of CPT-11 in the
present study (25 mg m–2 week–1) was much lower than the multi-
institutional study (45 mg m–2 week–1) and Kobayashi’s study
(45 mg m–2). On the other hand, DI of CDDP in the present study
(30 mg m–2 week–1) was higher than those in the multi-institutional
study (20 mg m–2 week–1) and Kobayashi’s study (25 mg m–2).
Thus, DI of CDDP may be related to the high incidence of diar-
rhoea in the present study. Furthermore, the sequence of adminis-
tration of these 2 agents in the present study, CDDP before
CPT-11, may develop higher AUC of CPT-11 and SN-38 than the
inverted sequence. Therefore, high DI of CDDP and sequence of
administration of these 2 drugs in the present study may have
produced high AUC of CPT-11 and SN-38, and may have resulted
in the increased incidence of severe diarrhoea. If the major
obstacle of this fractionated administration of CPT-11 and CDDP
is presumed to be diarrhoea during neutropenia, which may cause
sepsis, effective prophylaxis of diarrhoea with loperamide will be
important, and early administration of rhG-CSF may be necessary
in the following study. Furthermore, prediction of patients so
sensitive to CPT-11 and SN-38 as to develop severe diarrhoea also
appears to be useful (Ando et al, 2000). 
In conclusion, a fractionated administration of CPT-11 and
CDDP was confirmed to be highly effective for advanced NSCLC
with manageable toxicities. The treatment outcomes of the present
study were superior or at least comparable to the results of
previous multi-institutional trials of a combination of CPT-11 plus
CDDP (Masuda et al, 1998, 1999; DeVore et al, 1999; Niho et al,
1999). Recently, superiority of 2-drug combinations of one of the
newly developed agents, vinorelbine or paclitaxel, with CDDP to
the representative CDDP-based chemotherapy in the 1980s such
as CDDP plus vindesine or etoposide was reported in prospective
randomized trials (Le Chevalier et al, 1994; Bonomi et al, 2000).
However, no definitive conclusion was obtained in the 2 Japanese
multi-institutional randomized trials comparing CPT-11 plus
CDDP with CDDP plus vindesine (Masuda et al, 1999; Niho et al,
1999), although superiority of CPT-11 plus CDDP for stage IV
patients was shown by the subset analysis of one trial (Masuda 
et al, 1999). Therefore further studies to establish the usefulness of
the fractionated combination of CPT-11 and CDDP by comparing
survival of this combination with that of a combination used in the
Japanese multi-institutional trials will be warranted. 
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